You searched for venetoclax - Page 2 of 29

ASCO 2023: Dr. Jennifer Woyach on Combination Ibrutinib, Venetoclax, and Obinutuzumab for Previously Untreated CLL

September 15, 2023

In the setting of the COVID-19 pandemic, progression-free survival with first-line ibrutinib + venetoclax + obinutuzumab treatment was not superior to ibrutinib + obinutuzumab for older patients with previously untreated CLL. Follow-up remains ongoing, and many patients in the ibrutinib + venetoclax + obinutuzumab arm achieved undetectable measurable residual disease.

Venetoclax

August 31, 2023

CLL Medicine Cabinet – Venetoclax

Initial Results of a Study of an Accelerated Dose Ramp-Up of Venetoclax in CLL

August 16, 2023

An accelerated five-day venetoclax in hospital ramp-up, called SAVE (Safe Accelerated Venetoclax Escalation), can be done safely for most chronic lymphocytic leukemia (CLL) patients with an acceptably low risk of tumor lysis syndrome (TLS).

Final 7-Year Follow-Up Substudy of Using Venetoclax Combined with Rituximab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

August 16, 2023

In this final long-term analysis of the groundbreaking MURANO trial, progression-free survival (PFS) and overall survival (OS) benefits for venetoclax-rituximab (VenR) over bendamustine-rituximab (BR) were once again confirmed.

ASH 2022: Dr. Bill Wierda on Ibrutinib Combined with Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia (CLL)

April 26, 2023

The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)

ASH 2022: Dr. Arnon Kater on Long-Term Immune Changes After Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

April 10, 2023

Study shows that patients with relapsed/refractory CLL recovered immune function after fixed-duration treatment with venetoclax + rituximab.

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

March 24, 2023

Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome

March 16, 2023

Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

March 16, 2023

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: venetoclax – Page 2

ASCO 2023: Dr. Jennifer Woyach on Combination Ibrutinib, Venetoclax, and Obinutuzumab for Previously Untreated CLL

Venetoclax

Initial Results of a Study of an Accelerated Dose Ramp-Up of Venetoclax in CLL

Final 7-Year Follow-Up Substudy of Using Venetoclax Combined with Rituximab for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

ASH 2022: Dr. Bill Wierda on Ibrutinib Combined with Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Arnon Kater on Long-Term Immune Changes After Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT